Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Molecular Devices' foundational planar patch-clamp patent upheld by European Patent Office

Molecular Devices today announced that European Patent Office (EPO) has upheld Molecular Devices foundational planar patch-clamp patent (EP No 1 040 349 B1). The board will issue a written decision to this effect in the near future. The ruling will be the final determination of the EPO and cannot be appealed.

19 May 2010

NAC therapy shows promise for patients with mild IPF

A new therapy shows promise for patients with mild idiopathic pulmonary fibrosis. According to researchers in Japan, inhaled N-acetylcysteine monotherapy preserves more lung function in some idiopathic pulmonary fibrosis patients than no therapy.

19 May 2010

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.

19 May 2010

KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection

The data from the initial clinical studies with KB001, a novel antibody fragment against PcrV on Pseudomonas aeruginosa (Pa) bioengineered by KaloBios Pharmaceuticals, Inc. and partnered with sanofi pasteur, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis, where Pa plays an important role in the disease.

18 May 2010

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

FibroGen, Inc. today announced that administration of investigational therapy FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), reversed the process of fibrosis in a preclinical model of radiation-induced lung fibrosis, a finding that has implications for treating multiple types of fibrotic disease.

18 May 2010

Ambry Genetics launches AmbryScreen test for genetic screening of severe, common childhood diseases

Ambry Genetics announced today at the American College of Obstetricians and Gynecologists annual clinical meeting the launch of AmbryScreen™, a genetic screening test used to identify carriers of some of the most severe and common childhood diseases affecting pan-ethnic populations.

18 May 2010

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans.

17 May 2010

FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF

NeoPharm, Inc., announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan-drug designation for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

17 May 2010

DARA BioSciences commences $10M underwritten public offering

DARA BioSciences, Inc. announced today that it has commenced an underwritten public offering of $10 million of units comprised of shares of common stock and warrants. The company intends to grant the underwriter in the offering an option to purchase up to $1.5 million of additional units to cover any over-allotments.

17 May 2010

Treatment with MP-376 reduces P. aeruginosa in CF patients: Research

A new possible treatment to treat P. aeruginosa in cystic fibrosis patients appears to be promising, according to research to be presented at the ATS 2010 International Conference in New Orleans.

17 May 2010

Data from RGN-259 study published in Archives of Ophthalmology

RegeneRx Biopharmaceuticals, Inc. announced today the publication of the first human data from a case study of patients evaluated with its ophthalmic product candidate RGN-259. The data have been published in the May 2010 issue of Archives of Ophthalmology, an American Medical Association peer-reviewed journal.

14 May 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.

14 May 2010

Aradigm reports total revenue of $4.0M for first-quarter 2010

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2010.

13 May 2010

Increased IR associated with HCC development in chronic HCV-infected patients

Recent studies have demonstrated that type 2 diabetes mellitus (DM) is associated with high risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C. Insulin resistance (IR), which correlates inversely with circulating adiponectin concentration, is a consistent finding in patients with type 2 DM.

13 May 2010

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Pfizer Inc. and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension.

13 May 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the first quarter, ended March 31, 2010.

12 May 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Capstone Therapeutics announced today it has completed a limited analysis of a subset of data from the second of its two ongoing AZX100 Phase 2a clinical trials in keloid scarring. The clinical trial will continue to its planned 12-month endpoints.

12 May 2010

Pro-Pharmaceuticals completes $6 million private placement with 10X Fund

Pro-Pharmaceuticals, Inc., today announced that it has closed the $570,000 final tranche to complete a $6 million private placement with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants.

11 May 2010

Gene patenting policies affect patient access to testing for disease-causing genes: Study

Policies allowing genes to be patented can make it more difficult for patients to access testing for important disease-causing gene mutations, according to a series of papers in a special online supplement published by Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.

7 May 2010

Judge's ruling gives 'wide latitude' to plaintiffs' in lawsuits against Omniscan imaging drug

ProPublica: In a key ruling, "a federal judge has given plaintiffs' lawyers wide latitude to present evidence and expert testimony that GE's Omniscan imaging drug caused a crippling disease in MRI patients."

7 May 2010

Fibrosis News and Research

Further Reading

Molecular Devices' foundational planar patch-clamp patent upheld by European Patent Office

NAC therapy shows promise for patients with mild IPF

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

Ambry Genetics launches AmbryScreen test for genetic screening of severe, common childhood diseases

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF

DARA BioSciences commences $10M underwritten public offering

Treatment with MP-376 reduces P. aeruginosa in CF patients: Research

Data from RGN-259 study published in Archives of Ophthalmology

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

Aradigm reports total revenue of $4.0M for first-quarter 2010

Increased IR associated with HCC development in chronic HCV-infected patients

Pfizer to acquire terguride from Ergonex Pharma GmbH for treatment of PAH

Pro-Pharmaceuticals reports net loss applicable to common stock of $2.8M for first-quarter 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Pro-Pharmaceuticals completes $6 million private placement with 10X Fund

Gene patenting policies affect patient access to testing for disease-causing genes: Study

Judge's ruling gives 'wide latitude' to plaintiffs' in lawsuits against Omniscan imaging drug

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News